CheckMate 227, phase III clinical trial investigated treatment-related safety and activity of ipilimumab plus nivolumab as frontline therapy in NSCLC patients.58 Based on its results, the US FDA authorized the use of ipilimumab and nivolumab as a first-line therapy for NSCLC patients expressing high metastatic PD-L1.59 This evidence concerns the gene CD274 and non-small cell lung carcinoma.